Eisai Inc. Opens New U.S. Headquarters on ON3 Campus in Nutley, New Jersey, Amplifying Its Commitment to Life Sciences Innovation and Collaboration

Move supports Eisai’s new hybrid workstyle and human health care mission to deliver life-changing therapies and health-related solutions

Eisai Inc., the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., today announced that the company has relocated its U.S. headquarters to the ON3 Campus [at 200 Metro Boulevard] in Nutley, New Jersey. This move offers employees a dynamic, technologically advanced work environment that further enables Eisai’s commitment to innovation and the pursuit of its human health care (hhc) mission to deliver life-changing therapies and health-related solutions to help people live healthier and more fulfilling lives.

Eisai’s move to the ON3 Campus will help the company continue its work to address unmet patient and caregiver needs and apply its scientific expertise and technology to make a meaningful treatment impact in oncology and neurology. The 200 Metro facility is designed to nurture the company’s hybrid flexible working model, which allows for deep collaboration and interaction among colleagues while encouraging them to embrace new ways of working.

“Eisai’s decision to relocate to the ON3 Campus is a demonstration of our ongoing commitment to New Jersey and to be part of this diverse life sciences hub,” said Tatsuyuki Yasuno, President, Eisai Inc. & Americas Region. “With a 400-seat auditorium and an Innovation Center at our new U.S. headquarters, we are establishing dedicated space and resources to educate and motivate our employees, as well as a forum to hear from patients, advocacy partners and the community. Through this collaboration, we can make a positive impact on people and society and fulfill our human health care mission.”

Eisai’s U.S. headquarters will bring approximately 800 jobs to the Nutley/Clifton area and, at full capacity, the new facility will accommodate 1,300 employees. The company’s U.S. presence also includes three early-stage discovery research centers, as well as commercial, clinical development and global demand organizations.

“We recently met with the leadership of Eisai, and we were extremely impressed,” said Township of Nutley Mayor Mauro G. Tucci. “Eisai is a global pharmaceutical company, committed to human health care, who values the communities where they work. We welcome Eisai to Nutley and look forward to working with them to enhance our Township. We thank them for their investment in our community and the surrounding area.”

“New Jersey has established itself as the global epicenter of the biopharmaceutical industry, and we are proud to see an innovative company like Eisai call Clifton home,” said James Anzaldi, Mayor, City of Clifton. “Given the urgency for new treatments for cancer and neurologic conditions, we look forward to seeing the important work Eisai is doing make a positive societal impact and improve the lives of our residents and people around the world.”

About Eisai Inc.

At Eisai Inc., human health care (hhc) is our mission and is the shared purpose that connects us to those we serve creating a network of powerful relationships that enables us to identify, understand and work to address the needs of people throughout their lives. We boldly push past the boundaries of science and aim to deliver life-changing therapies and health-related solutions that matter to people and society. We bring together science, technology and real-world expertise to pursue a world free from cancer, Alzheimer’s disease and other neurodegenerative diseases.

Everything we do is guided by the simple principle that patients and their families come first, and we have a responsibility to listen to and learn from them.

Eisai Inc. is the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd. The company’s presence in the U.S. includes three discovery centers as well as commercial, clinical development and global demand organizations. To learn more about Eisai, please visit us at www.eisai.com/US and follow us on Twitter and LinkedIn. For more information on our work in neurology, please visit the Eisai U.S. Neurology LinkedIn page.